Martin Tallman
马丁·塔尔曼
MD
Chief, Leukemia Service白血病科主任
👥Biography 个人简介
Chief of the Leukemia Service at Memorial Sloan Kettering, renowned for defining the curative role of ATRA and arsenic trioxide in APL. His translational and clinical research established APL as one of the most curable leukemias, influencing global treatment standards.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
APL Differentiation Therapy
Conducted foundational US trials of all-trans retinoic acid (ATRA) combined with arsenic trioxide in APL, achieving cure rates above 90% and eliminating the need for cytotoxic chemotherapy in low-risk patients.
AML Induction and Consolidation
Refined induction and post-remission strategies for non-APL AML, including transplant decision-making frameworks that optimized long-term outcomes across risk groups.
Representative Works 代表性著作
All-trans retinoic acid in APL: a decade of experience
Blood (2002)
Comprehensive analysis of ATRA-based therapy outcomes, cementing differentiation therapy as the standard approach and inspiring global adoption of chemotherapy-free APL regimens.
Arsenic trioxide and ATRA without chemotherapy in APL
New England Journal of Medicine (2013)
Demonstrated non-inferiority of ATO+ATRA versus standard chemotherapy in low-risk APL, establishing a chemotherapy-free curative regimen adopted worldwide.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Elihu Estey
Fred Hutchinson Cancer Center
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Naval Daver
The University of Texas MD Anderson Cancer Center
Courtney DiNardo
The University of Texas MD Anderson Cancer Center
关注 马丁·塔尔曼 的研究动态
Follow Martin Tallman's research updates
留下邮箱，当我们发布与 Martin Tallman（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment